1. Home
  2. ARQT vs BBU Comparison

ARQT vs BBU Comparison

Compare ARQT & BBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$24.19

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Logo Brookfield Business Partners L.P. Limited Partnership Units

BBU

Brookfield Business Partners L.P. Limited Partnership Units

HOLD

Current Price

$31.46

Market Cap

3.1B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARQT
BBU
Founded
2016
2016
Country
United States
Bermuda
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Engineering & Construction
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.1B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
ARQT
BBU
Price
$24.19
$31.46
Analyst Decision
Strong Buy
Buy
Analyst Count
6
5
Target Price
$34.00
$39.40
AVG Volume (30 Days)
1.1M
46.8K
Earning Date
05-05-2026
05-01-2026
Dividend Yield
N/A
0.79%
EPS Growth
88.79
N/A
EPS
N/A
N/A
Revenue
$376,072,000.00
N/A
Revenue This Year
$34.46
N/A
Revenue Next Year
$29.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
91.34
N/A
52 Week Low
$12.42
$19.91
52 Week High
$31.77
$37.75

Technical Indicators

Market Signals
Indicator
ARQT
BBU
Relative Strength Index (RSI) 52.71 44.87
Support Level $22.56 $29.90
Resistance Level $25.03 $36.93
Average True Range (ATR) 0.96 1.38
MACD 0.35 0.23
Stochastic Oscillator 77.75 46.92

Price Performance

Historical Comparison
ARQT
BBU

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

About BBU Brookfield Business Partners L.P. Limited Partnership Units

Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.

Share on Social Networks: